We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Noureddine Benjaafar
Jun 23, 2022
OLAPARIB 300MGbid
Charles Maack
Jun 23, 2022
start Lu177-PSMA-617 (assuming it is available at your Institution)
Comment deleted by Moderator.
Bernard Riley
Jun 24, 2022
Olaparib
Comment deleted by Moderator.
nadire kucukoztas
Jun 24, 2022
start olaparib 300mg BID
Andrea Sporchia
Jun 24, 2022
start olaparib 300mg BID
alice goodman
Jun 24, 2022
Start olaparib
Samaneh Sarbaz
Jun 24, 2022
Cabazitaxel
Philip von Lintel MD
Jun 24, 2022
I agree with Charles Maack ; To theoretically approach specific mets and nondetectable micromets ;; perhaps less toxicity
Shusit Parnitvitidkun
Jun 25, 2022
Start olaparib
Comment deleted by Moderator.
Javier Cassinello
Jul 16, 2022
OLAPARIB ( we have a biomarker)
Angela Tiganas
Jul 16, 2022
4
Namita Vinayek
Jul 17, 2022
Olaparib
Philip von Lintel MD
Jul 18, 2022
in addition to the Lu 177 PSMA ( +/-) Radioguided surgery , MRI guided focused ultrasound (MRI ) ; for applicable targets ; Consider adequate additional support / appropriate use of ? metformin , HIIT ( physical conditioning ) , diet , probiotics ... every little bit !
juliana chaves
Feb 26, 2023
start olaparib 300mg BID
Franz Stoiber
Feb 27, 2023
Prior Olaparib, then go for Lu just to maintain his haematological reserve as long as possible
but check performance for delivering Cabazitaxel as long or soon as it possible
Dec 18, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Noureddine Benjaafar
Jun 23, 2022
Charles Maack
Jun 23, 2022
Bernard Riley
Jun 24, 2022
nadire kucukoztas
Jun 24, 2022
Andrea Sporchia
Jun 24, 2022
alice goodman
Jun 24, 2022
Samaneh Sarbaz
Jun 24, 2022
Philip von Lintel MD
Jun 24, 2022
Shusit Parnitvitidkun
Jun 25, 2022
Javier Cassinello
Jul 16, 2022
Angela Tiganas
Jul 16, 2022
Namita Vinayek
Jul 17, 2022
Philip von Lintel MD
Jul 18, 2022
juliana chaves
Feb 26, 2023
Franz Stoiber
Feb 27, 2023
Dec 18, 2024
Pending Moderator approval.